about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Kyver­na Ther­a­peu­tics adds $60M to the bank as it pre­pares to show­case ear­ly CAR-T da­ta in lu­pus nephri­tis

Last year
Financing
Cell/Gene Tx

Mar­tin Shkre­li's old com­pa­nies se­cure $650,000 deal to sell Dara­prim amid bank­rupt­cy

Last year
Deals
Pharma

Up­dat­ed: EQRx sells it­self to an­oth­er Alex­is Borisy com­pa­ny, Rev­o­lu­tion Med­i­cines, in all-stock deal

Last year
Deals

Bris­tol My­ers, As­traZeneca strike $510M set­tle­ment on PD-L1, CT­LA-4 patent law­suits

Last year
Pharma
Law

Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Last year
R&D

Bio­gen's $7.3B M&A deal, lay­offs; R&D shake­up at Pfiz­er, As­traZeneca; Scal­ing rare dis­ease meds; Q2 earn­ings; and ...

Last year
Weekly

Cyrus Moza­yeni fol­lows ADC 'bea­con' to Pheon CEO role; BeiGene los­es busi­ness chief to Te­va

Last year
Peer Review

As­traZeneca picks up Pfiz­er’s rare dis­ease gene ther­a­pies, taps new R&D leader as Mene Pan­ga­los steps down

Last year
People
Deals

Af­ter years of de­lay, Roche takes one of Spark’s he­mo­phil­ia gene ther­a­pies in­to PhI­II, drops an­oth­er

Last year
R&D
Cell/Gene Tx

GSK bull­ish on RSV vac­cine bat­tle against Pfiz­er, ships first Arexvy dose

Last year
Pharma
Marketing

British bil­lion­aire Joe Lewis in­dict­ed for al­leged in­sid­er trad­ing scheme in­volv­ing Mi­rati, Sol­id Bio shares

Last year
People

GSK pulls plans to mar­ket ane­mia drug in EU and oth­er mar­kets, cit­ing 're­duced op­por­tu­ni­ty'

Last year
Pharma

Astel­las en­lists Pep­tiDream in search for pro­tein de­graders as it looks to act fast in hot field

Last year
Deals

Up­dat­ed: Roche pays Al­ny­lam $310M cash to part­ner on RNAi can­di­date for heart dis­ease

Last year
Deals

Gilead ax­es PhI­II tri­al for CD47 drug in lat­est set­back for $4.9B buy­out

Last year
R&D

2023 Women in Bio­phar­ma R&D; Biotech hope­ful for re­bound even as new wave of lay­offs hit; No­var­tis' siR­NA buy­out; and ...

Last year
Weekly

'We sim­ply can­not sus­tain': Idor­sia weighs lay­offs, deals, pipeline trims to bring cost down

Last year
People

Codex­is cuts 25% of staff, slash­es drug pro­grams while dou­bling down on RNAi tech

Last year
People
R&D

Im­munother­a­py dur­ing surgery? Surge Ther­a­peu­tics nabs $32M to ex­pand clin­i­cal plans af­ter first dos­ing

Last year
Financing

Amarin lays off US sales­force, names new CEO in shake­up

Last year
R&D

No­var­tis cuts PhII obe­si­ty can­di­date as it fi­nal­izes San­doz spin­off

Last year
R&D
Pharma

Ar­genx looks for quick la­bel ex­pan­sion for sub­cu­ta­neous Vyv­gart with PhII da­ta — shares soar

Last year
R&D
Pharma

Eli Lil­ly’s M&A Fri­day; No­var­tis' TIG­IT breakup; One big hire and one big ex­it; Re­verse merg­er, shut­down and white ...

Last year
Weekly

The­seus goes back to pre­clin­i­cal mode af­ter ax­ing lead tar­get­ed ther­a­py over tol­er­a­bil­i­ty con­cerns, shares plum­met

Last year
R&D
First page Previous page 891011121314 Next page Last page
A service from the Financial Times